Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$200.79
▼ $4.30 (-2.1%)
Market data updated: 09/19 07:40 AM
Fundamentals updated: 09/18/2026
News analyzed: 09/19/2026
Market Cap
$10.48B
Day Range
$200.71 - $205.79
52-Week Range
$121.06 - $244.89
Beta
—
Next Earnings
20.10.2026
Support
$186.05
Resistance
$244.89
MOH is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+11.7% (1Y)
Strengths: 7/30 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟡 Mixed
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Liquidity risk
Current ratio: 1.69
Risk
Biggest negative driver
DCF Fair Value
Estimated fair value: -$227.87 vs. price $200.79 (-213.5%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
49
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
3d ago · $214.07
Evidence: FOMO score jumped from 10 to 40 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
37
Quality
42
Value
38
Momentum
56
Risk
48
Sentiment
80
Fundamental
47
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Molina Healthcare Inc. has primarily focused on its upcoming **third-quarter 2026 earnings report**, scheduled for October 21, 2026, alongside a conference call. While broader healthcare industry trends—such as innovation in digital health and strong stock performance—are noted, Molina itself is not prominently highlighted beyond this earnings announcement. The sources are limited, so no deeper operational or financial details are available.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Molina Healthcare Inc. News trend score: 80. Reason: 9 of the last 20 articles are positive, versus 4 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
17
🎯 Conviction (vs. Emotion)
36
Psychology
44
Fundamentals
47
Technical
56
Valuation
38
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+3%
Market Narrative
55
Fundamental Reality
36
Narrative Gap
+19
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The dominant **herding** behavior in MOH reflects a market where participants are aligning with peers rather than acting on independent signals. The stock’s underperformance today (-3.3% vs. -5.7% peers) suggests traders are reacting to relative weakness, not fundamental shifts. Meanwhile, euphoria (19) persists due to extreme positive sentiment (100/100) despite weak momentum, indicating selective optimism. The key question is whether this herding will persist or if a break from peer trends could trigger a re-evaluation. The narrative gap (28) further implies a disconnect between market perception and underlying reality, reinforcing herd-driven behavior.
Updated: 09/09/2026, 01:02 AM
What could change this?
🧠 Market Brain events driving this
📈 12D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 67/100
🔴 Weakest match
Morgan Housel — 14/100
🗣️ Why do they disagree?
This stock sparks a sharp divide among the methodologies, with some models seeing cautious optimism and others outright warning against it. Charles Mackay and Samuel Armstrong Nelson both flag signs of crowd behavior or cyclical positioning that could favor entry, scoring it near the mid-60s, suggesting a speculative or late-cycle appeal. In contrast, the efficient-market camp and Livermore’s trend-following approach are far more reserved, scoring it in the low 50s, as they see little clear momentum or alpha potential. Meanwhile, the most conservative voices—like Graham, Veblen, and Lynch—dismiss it outright, scoring it in the teens and 20s, citing lack of stability, overvaluation, or unsustainable growth patterns. The gap between the highest and lowest scores (66 vs. 17) underscores a fundamental disagreement: whether this stock is a speculative play riding a wave of hype or a risky bet with no fundamental edge.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 67
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 58
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 57
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 51
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 51
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 50
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 46
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 40
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 39
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 35
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 28
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 27
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 26
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 25
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 19
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 14
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🟡 Indicators are mixed — no clear bias (4 bullish · 4 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
13.1%
Operating Margin
1.7%
Net Margin
1.0%
EBITDA Margin
2.1%
ROE
11.6%
ROA
3.0%
ROIC
—
EPS
$8.93
Cash
$4.25B
Total Debt
$3.77B
Current Ratio
1.69
Debt/Equity
0.93
How is Fair Value calculated? →
Current Price
$200.79
Estimated Fair Value (DCF)
-$227.87
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-213.5%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
12.5%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 12.5% | $-715.75M | $-656.65M |
| 2 | 10.0% | $-787.53M | $-662.85M |
| 3 | 7.5% | $-846.75M | $-653.85M |
| 4 | 5.0% | $-889.17M | $-629.91M |
| 5 | 2.5% | $-911.40M | $-592.35M |
Base FCF (last actual year)
$-636.00M
Terminal Value
$-14.37B
Present Value of Terminal Value
$-9.34B
Enterprise Value
$-12.54B
Net Debt
$-482.00M
Equity Value
$-12.05B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$76.92
Tangible Book Value per Share (Tangible NAV)
$35.43
Sentiment based on basic keywords (not AI) — 9 positive, 7 neutral, 4 negative out of the last 20 articles.
Benzinga · 15.9.2026
Yahoo · 10.9.2026
GuruFocus.com · 10.9.2026
Benzinga · 10.9.2026
Stocktwits · 9.9.2026
Yahoo · 9.9.2026
StockStory · 8.9.2026
Yahoo · 8.9.2026
StockStory · 3.9.2026
Yahoo · 3.9.2026
Yahoo · 2.9.2026
Zacks · 2.9.2026
Yahoo · 2.9.2026
Business Wire · 2.9.2026
Yahoo · 1.9.2026
Zacks · 1.9.2026
Yahoo · 31.8.2026
Stocktwits · 31.8.2026
Yahoo · 28.8.2026
Zacks · 28.8.2026
Molina Healthcare Inc (MOH) currently has a StockIQ AI score of 49/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
MOH currently scores 49/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, MOH's estimated fair value is -$227.87, which is 213.5% below the current price of $200.79. This is one valuation model among several signals in the fair-value category, not a price target.
MOH's technical score is 56/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Current ratio: 1.69; Price is above the 200-day average; MACD histogram is positive — rising momentum.
Based on the real signals StockIQ computed: Estimated fair value: -$227.87 vs. price $200.79 (-213.5%); Operating margin is eroding over time; Calmar: -0.22 (3y annualized return -15.2% / max drawdown 70.8%).
StockIQ has no recorded dividend payment history for MOH.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Bacon Debra | Tax Withholding in Shares | 1.7.2026 | 183 | -183 | $232.55 |
| BRASIER BARBARA L | Grant/Award from Employer | 1.7.2026 | 237 | +237 | $232.55 |
| GROHOWSKI LEO P | Grant/Award from Employer | 1.7.2026 | 237 | +237 | $232.55 |
| SOISTMAN FRANCIS S JR | Grant/Award from Employer | 1.7.2026 | 237 | +237 | $232.55 |
| Lockhart Stephen H | Grant/Award from Employer | 1.7.2026 | 237 | +237 | $232.55 |
| Schapiro Richard M | Grant/Award from Employer | 1.7.2026 | 237 | +237 | $232.55 |
| WOLF DALE B | Grant/Award from Employer | 1.7.2026 | 237 | +237 | $232.55 |
| ZORETIC RICHARD C | Grant/Award from Employer | 1.7.2026 | 237 | +237 | $232.55 |
| ROMNEY RONNA | Grant/Award from Employer | 1.7.2026 | 237 | +237 | $232.55 |
| ORLANDO STEVEN J | Grant/Award from Employer | 1.7.2026 | 237 | +237 | $232.55 |
| BRASIER BARBARA L | Grant/Award from Employer | 1.7.2026 | 5,818 | +237 | $232.55 |
| ROMNEY RONNA | Grant/Award from Employer | 1.7.2026 | 17,869 | +237 | $232.55 |
| ORLANDO STEVEN J | Grant/Award from Employer | 1.7.2026 | 17,967 | +237 | $232.55 |
| WOLF DALE B | Grant/Award from Employer | 1.7.2026 | 15,633 | +237 | $232.55 |
| SOISTMAN FRANCIS S JR | Grant/Award from Employer | 1.7.2026 | 907 | +237 | $232.55 |
| GROHOWSKI LEO P | Grant/Award from Employer | 1.7.2026 | 1,542 | +237 | $232.55 |
| ZORETIC RICHARD C | Grant/Award from Employer | 1.7.2026 | 9,389 | +237 | $232.55 |
| Schapiro Richard M | Grant/Award from Employer | 1.7.2026 | 12,311 | +237 | $232.55 |
| Lockhart Stephen H | Grant/Award from Employer | 1.7.2026 | 4,384 | +237 | $232.55 |
| Bacon Debra | Tax Withholding in Shares | 1.7.2026 | 21,636 | -183 | $232.55 |
| Barlow Jeff D. | Grant/Award from Employer | 30.6.2026 | 138 | +138 | $147.51 |
| WOYS JAMES | Grant/Award from Employer | 30.6.2026 | 144 | +144 | $147.51 |
| Bacon Debra | Grant/Award from Employer | 30.6.2026 | 23 | +23 | $147.51 |
| WOYS JAMES | Grant/Award from Employer | 30.6.2026 | 90,178 | +144 | $147.51 |
| Barlow Jeff D. | Grant/Award from Employer | 30.6.2026 | 67,313 | +138 | $147.51 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
3,079,899 shares short as of 2026-08-31 · vs. 2,935,657 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
54.1% of trading volume this week was short selling, vs. 46.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology